BMS Reports Strong H1 2019 Performance with Opdivo Generating $3.624 Billion in Sales
Jul 26, 2019 11:09
CST Updated
11:09
GSK
Pharmaceutical R&D Manufacturer
On July 25, BMS announced its financial results for the first half of 2019, with total revenue reaching $12.193 billion, a 12% increase.
2019 H1 Bristol-Myers Squibb Core Drug Sales Revenue (USD 100 million)
Original Title: 2019 H1, BMS Core Drug Sales Revenue! Opdivo $3.624 Billion
*Disclaimer: This article was written by an author contributing to Sina Medical News. The views expressed are solely those of the author and do not represent the position of Sina Medical News.
